DB-OTO Gene Therapy for Inherited Deafness.
Vassili Valayannopoulos, Manohar Bance, Daniela S Carvalho...
https://pubmed.ncbi.nlm.nih.gov/41085057/Actively Recruiting
Led by Regeneron Pharmaceuticals · Updated on 2026-08-05
36
Participants Needed
17
Research Sites
156 weeks
Total Duration
Researchers are evaluating DB-OTO, an investigational gene therapy, for children, infants, adolescents, and adults who have severe to profound hearing loss caused by mutations in the otoferlin gene. This study aims to learn about the safety of DB-OTO, how well it is tolerated without ongoing discomfort, and how effective it is in improving hearing abilities. Participants will receive DB-OTO through one of several dosing approaches including unilateral intracochlear injection, bilateral intracochlear injection based on safety and efficacy data from an initial phase, or either unilateral or bilateral dosing. The trial is open-label and includes sequential cohorts to evaluate safety, tolerability, and efficacy. The study consists of different parts where dosing and monitoring are tailored accordingly. During the study, participants will undergo various assessments to measure hearing sensitivity using Pure Tone Audiometry and Auditory Brainstem Response tests, as well as speech perception and auditory skill evaluations. Safety will be monitored by tracking treatment-emergent adverse events up to week 104. Participants and their guardians will be closely followed for over two years to evaluate hearing improvements and any changes in speech abilities or safety outcomes.
CONDITIONS
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
C
Clinical Trials Administrator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Regeneron Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DB‑OTO gene therapy | Cochlear implant (standard care) |
|---|---|---|
| What it is | An adeno‑associated virus (AAV) based gene replacement therapy delivering functional otoferlin via sequential cohorts evaluated in a one‑arm interventional trial | A surgical device implant that bypasses the dysfunctional otoferlin synapse to stimulate the auditory nerve, used for OTOF‑related profound hearing loss |
| Role in this study | Investigational therapy administered in sequential dose/biodistribution or cohort stages | Not part of the trial; represents external standard care not evaluated within this protocol |
| Primary use | To replace the missing otoferlin protein and restore synaptic hearing function in OTOF‑related hearing loss | To bypass the presynaptic defect by directly stimulating the auditory nerve to enable hearing |
| How it is given or performed | Administered via surgical injection into the cochlea according to cohort‑specific dosing protocol | Surgically implanted electrode array placed in the cochlea under general anesthesia |
| Evidence status | Early phase interventional data; outcomes pending full trial results | Decades of clinical experience showing improved speech and sound perception in OTOF‑related auditory neuropathy |
| Important risks | Potential surgical and vector‑related risks under investigation | Surgical risks such as infection or device failure; well‑characterized complications |
| Important limitations | Unknown long‑term durability, redosing capability, and real‑world implementation logistics | Bypasses rather than restores normal hearing; requires external device and ongoing maintenance |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 104 weeks
Participants receive DB-OTO gene therapy via intracochlear dosing, which may be unilateral or bilateral depending on the study part and safety data.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Vassili Valayannopoulos, Manohar Bance, Daniela S Carvalho...
https://pubmed.ncbi.nlm.nih.gov/41085057/Regeneron Pharmaceuticals
Lead Sponsor